A

Akero Therapeutics
D

AKRO

32.660
USD
1.46
(4.68%)
Market Open
Volume
14,390
EPS
-4
Div Yield
-
P/E
-9
Market Cap
2,279,640,174
OverviewSignalsIdeasNews
Related Instruments
    SUSHIUSD
    SUSHIUSD
    0.01705
    (2.25%)
    0.77440 USD
    AAVEUSD
    AAVEUSD
    1.602
    (0.96%)
    168.884 USD
    B
    BAL
    0
    (0%)
    0.000000 USD
    C
    COMP
    -0.27500
    (-4.16%)
    6.33000 USD
    S
    SNX
    -0.380
    (-0.33%)
    115.300 USD
    More
News

Title: Akero Therapeutics

Sector: Healthcare
Industry: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.